한글목차

세계의 HLA 타이핑 시장 규모는 2025년 17억 달러에서 2030년 23억 달러로 성장할 것으로 예측되며, 2025년부터 2030년까지 예측 기간 동안 CAGR 6.0%로 확대될 전망입니다.

이식은 만성 투석 의존성 말기 신장 질환을 앓고있는 많은 환자와 심장 이식, 간 이식 및 골수 이식을 필요로하는 환자에게 바람직한 치료 옵션입니다. 지난 10년동안 HLA 타이핑 기술, 항체 모니터링 및 진단 방법, 각사가 개발한 전용 소프트웨어에 있어서, 큰 진보가 있습니다. 이러한 기술 혁신은 장기 이식 프로세스에 불가결한 것이 되어, 정밀도와 신뢰성을 높이고, HLA 타이핑 시장의 확대를 촉진하는데 중요한 역할을 하고 있습니다.

최종 사용자별 세분화에서 HLA(인간 백혈구 항원) 타이핑 시장은 상업 서비스 제공업체, 병원 및 이식 센터, 연구소 및 학술 기관으로 분류됩니다. 상업 서비스 제공업체가 가장 높은 수익을 올리고 강력한 성장이 예상되고 있습니다.

HLA 타이핑 시장은 용도별로 진단(기증자와 수령인의 크로스 매칭, 감염증 검사, 암 진단과 예방, 수혈 요법, 기타 진단 용도 등)과 연구로 분류됩니다. 이식을 받는 환자가 기증자로부터 감염증에 걸리는 리스크가 높아지고 있는 것이 주된 원인입니다.

HLA 타이핑 시장은 5개의 주요 지역(북미, 유럽, 아시아태평양, 라틴아메리카, 중동, 아프리카)으로 분류됩니다. 북미에서는 장기 이식과 줄기 세포 이식 수요 증가, 만성 질병과자가 면역 질환의 유병률의 상승, 고도의 분자진단 기술의 채용이 시장의 강력한 성장을 가져오고 있습니다. 이 지역은 기술 혁신과 연구의 중심지이며, HLA 타이핑 분야의 주요 기업의 대부분이 이 지역에 본사를 두고 있습니다. 그 결과, 차세대 시퀀싱(NGS)을 포함해 최첨단 기술이 급속히

본 보고서에서는 세계의 HLA 타이핑 시장에 대해 조사했으며, 제품 및 서비스별, 기술별, 용도별, 최종 사용자별, 지역별 동향 및 시장 진출기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

• HLA 타이핑 시장 개요
• HLA 타이핑 시장의 지역별 개요

제5장 시장 개요

• 소개
• 시장 역학
• 고객사업에 영향을 주는 동향/혼란
• 가격 분석
• 밸류체인 분석
• 공급망 분석
• 생태계 분석
• 투자 및 자금조달 시나리오
• 기술 분석
• 특허 분석
• 무역 분석
• 2025-2026년의 주된 회의와 이벤트
• 사례 연구 분석
• 규제 상황
• Porter's Five Forces 분석
• 주요 이해관계자와 구매 기준
• 미충족 요구
• HLA 타이핑 시장에서의 AI의 영향
• 2025년 미국 관세의 영향

제6장 HLA 타이핑 시장(제품 및 서비스별)

• 소개
• 시약 및 소모품
• 기기
• 소프트웨어 및 서비스

제7장 HLA 타이핑 시장(기술별)

• 소개
• 분자 분석 기술
• 비분자 분석 기술

제8장 HLA 타이핑 시장(용도별)

• 소개
• 진단
• 연구

제9장 HLA 타이핑 시장(최종 사용자별)

• 소개
• 상업 서비스 제공업체
• 병원과 이식 센터
• 연구기관 및 학술기관

제10장 HLA 타이핑 시장(지역별)

• 소개
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시 경제 전망
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 아시아태평양
  • 아시아태평양의 거시 경제 전망
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시 경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타

제11장 경쟁 구도

• 소개
• 주요 진입기업의 전략
• 수익 분석, 2020-2024년
• 시장 점유율 분석, 2024년
• 기업평가와 재무지표
• 제품/브랜드 비교
• 기업평가 매트릭스: 주요 진입기업, 2024년
• 기업평가 매트릭스: 스타트업/중소기업, 2024년
• 경쟁 시나리오

제12장 기업 프로파일

• 주요 진출기업
  • BD
  • THERMO FISHER SCIENTIFIC INC.
  • ILLUMINA, INC.
  • QIAGEN
  • BIO-RAD LABORATORIES, INC.
  • F. HOFFMANN-LA ROCHE LTD
  • CAREDX, INC.
  • WERFEN
  • DIASORIN SPA
  • TBG BIOTECHNOLOGY CORPORATION
  • FUJIREBIO
  • EUROBIO SCIENTIFIC
  • PACBIO
  • BAG DIAGNOSTICS GMBH
  • CREATIVE BIOLABS
• 기타 기업
  • HISTOGENETICS LLC
  • SCISCO GENETICS, INC.
  • INNO-TRAIN DIAGNOSTIK GMBH
  • BIONOBIS
  • TAKARA BIO INC.
  • KRISHGEN BIOSYSTEMS
  • SCIENCELL RESEARCH LABORATORIES, INC.
  • PROIMMUNE LTD.
  • BIOFORTUNA LIMITED
  • ALPHA BIOTECH LIMITED

제13장 부록

영문목차

The global HLA typing market is projected to grow from USD 1.7 billion in 2025 to USD 2.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.0% over the forecast period from 2025 to 2030. Transplantation continues to be the preferred treatment option for many patients suffering from chronic dialysis-dependent end-stage renal disease, as well as those requiring heart, liver, or bone marrow transplants. Over the past decade, significant advancements have been made in HLA typing technologies, antibody monitoring, diagnostic methods, and specialized software developed by various companies. These innovations have become integral to the organ transplantation process, enhancing precision and reliability, and have played a key role in driving the expansion of the HLA typing market.

The commercial service providers segment accounted for the highest growth rate in the HLA typing market, by product and service, during the forecast period.

Based on end-user segmentation, the HLA (Human Leukocyte Antigen) typing market is categorized into commercial service providers, hospitals and transplant centers, and research laboratories and academic institutions. Among these, commercial service providers generated the highest revenue and are expected to witness strong growth, driven by the global rise in organ and stem cell transplants, which require precise, high-throughput HLA typing for effective donor-recipient matching. Growing awareness of personalized medicine, advancements in molecular diagnostics, and the increasing adoption of next-generation sequencing (NGS) technologies are key factors fueling demand for more specialized reagents and kits.

.

The diagnostic applications segment held the largest market share in 2024.

The HLA typing market is categorized based on application into diagnostic applications-including donor-recipient cross-matching, infectious disease testing, cancer diagnosis and prevention, transfusion therapy, and other diagnostic uses-and research applications. The diagnostic application segment is projected to dominate the market throughout the forecast period, with infectious disease testing accounting for the largest share within this segment. This is largely due to the heightened risk transplant recipients face of acquiring infections from donors. Current donor epidemiological screening methods and laboratory diagnostics have limitations in accurately assessing these risks, making infectious disease testing a critical and continuously growing focus area within the diagnostic segment of the transplant diagnostics market.

The market in the North America region is expected to hold a significant market share for the HLA typing market in 2023.

The HLA typing market spans five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In North America, the market is experiencing strong growth driven by the increasing demand for organ and stem cell transplants, the rising prevalence of chronic and autoimmune diseases, and the adoption of advanced molecular diagnostic techniques. This growth is further supported by a well-established healthcare infrastructure, government initiatives such as the National Marrow Donor Program, and greater public awareness of the importance of accurate HLA matching. The region is a hub for innovation and research, with many leading companies in the HLA typing space headquartered in the region. As a result, cutting-edge technologies, including next-generation sequencing (NGS), are being rapidly adopted, further fueling market expansion.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side: 60% and Demand Side: 40%
• By Designation: Managers: 20%, CXOs & Directors: 30%, and Executives: 50%
• By Region: North America: 40%, Europe: 30%, Asia Pacific: 20%, Latin America: 5%, and Middle East & Africa: 5%

List of Key Companies Profiled in the Report

The prominent players in the HLA typing market are Becton, Dickinson and Company (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories, Inc. (US), Bruker (US), F. Hoffman-La Roche Ltd (Switzerland), Accelerate Diagnostics, Inc. (US), Alpha Biotech Limited (Israel), Bag Diagnostics GmbH (Germany), Caredx, Inc. (US), Creative Biolabs (US), Fujirebio Holdings Inc (Japan), Gendx (Netherlands), Hologic, Inc. (US), Histogenetics LLC (US), Hansa Biopharma AB (Sweden), Illumina, Inc. (US), Inno-Train Diagnostik GmbH (Germany), Immucor, Inc. (US), Krishgen Biosystems (India), Omixon Inc. (Hungary), PacBio (US), Proimmune Ltd (UK), Pacific Bioscience of California Inc. (US), TBG Diagnostics Limited (Australia), and Takara Bio Inc. (Japan), among others.

Research Coverage

This report studies the HLA typing market based on product & service, technology, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to buy this report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall HLA typing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (growing number of organ transplantation procedures, rising technological advancements in HLA typing, increasing funding for research activities, growing prevalence of infectious diseases), restraints (high cost of HLA typing products, limited reimbursements for target procedures), opportunities (rising adoption of cross-matching and chimerism testing procedures, growing awareness of organ donations), and challenges (limited number of organ donations and long waiting lists for transplantations, shortage of skilled professionals)
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals/launches in the HLA typing market
• Market Development: Comprehensive information about lucrative markets
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the HLA typing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the HLA typing market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Indicative list of secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
  • 2.2.2 END-USER-BASED MAPPING MARKET ESTIMATION
• 2.3 GROWTH FORECASTING MODEL
• 2.4 DATA TRIANGULATION AND MARKET BREAKDOWN
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HLA TYPING MARKET OVERVIEW
• 4.2 REGIONAL SNAPSHOT OF HLA TYPING MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising number of organ transplantation procedures
    • 5.2.1.2 Increasing technological advancements in sanger sequencing
    • 5.2.1.3 Growing funding and research activities
    • 5.2.1.4 Increasing prevalence of infectious and autoimmune diseases
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of hla typing products
    • 5.2.2.2 Limited reimbursement policies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Adoption of cross-matching and chimerism testing
    • 5.2.3.2 Growth opportunities in emerging markets
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled professionals
    • 5.2.4.2 Lack of standardization across laboratories
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE, BY INSTRUMENTS
  • 5.4.2 AVERAGE SELLING PRICE, BY REAGENTS
  • 5.4.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENTS
  • 5.4.4 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 R&D
  • 5.5.2 RAW MATERIAL PROCUREMENT & PRODUCT DEVELOPMENT
  • 5.5.3 MARKETING, SALES, AND DISTRIBUTION
  • 5.5.4 POST-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Sequence-based typing
    • 5.9.1.2 Next-generation sequencing
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Sample preparation & dna extraction technologies
    • 5.9.2.2 Bioinformatics and data analysis software
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Transplant diagnostics
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT SCENARIO (HS CODE 3822)
  • 5.11.2 EXPORT SCENARIO (HS CODE 3822)
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY GUIDELINES
    • 5.14.1.1 North America
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
      • 5.14.1.2.1 UK
      • 5.14.1.2.2 France
      • 5.14.1.2.3 Germany
    • 5.14.1.3 Asia pacific
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
    • 5.14.1.4 Latin America
      • 5.14.1.4.1 Brazil
      • 5.14.1.4.2 Mexico
    • 5.14.1.5 Middle East & Africa
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCE ANALYSIS
  • 5.15.1 BARGAINING POWER OF SUPPLIERS
  • 5.15.2 BARGAINING POWER OF BUYERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 KEY BUYING CRITERIA
• 5.17 UNMET NEEDS
• 5.18 IMPACT OF AI ON HLA TYPING MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 MARKET POTENTIAL OF HLA TYPING PRODUCTS FOR PRE TRANSPLANT EVALUATION
  • 5.18.3 AI USE CASES
  • 5.18.4 KEY COMPANIES IMPLEMENTING AI
• 5.19 IMPACT OF 2025 US TARIFF
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
  • 5.19.3 PRICE IMPACT ANALYSIS
  • 5.19.4 IMPACT ON COUNTRY/REGION
    • 5.19.4.1 Us
    • 5.19.4.2 Europe
    • 5.19.4.3 Asia pacific
  • 5.19.5 IMPACT ON END-USE INDUSTRIES

6 HLA TYPING MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & CONSUMABLES
  • 6.2.1 INCREASED DEMAND FOR SPECIALIZED CONSUMABLES TO DRIVE MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 NEED FOR DONOR-RECIPIENT MATCHING AND IMMUNOGENETIC RESEARCH TO AID GROWTH
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 GROWING DEMAND FOR ADVANCED AND USER-FRIENDLY SOFTWARE TO BOOST MARKET

7 HLA TYPING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 MOLECULAR ASSAY TECHNOLOGIES
  • 7.2.1 PCR-BASED MOLECULAR ASSAYS
    • 7.2.1.1 Sequence-specific primer-PCR
      • 7.2.1.1.1 Higher speed, precision, and affordability to favor growth
    • 7.2.1.2 Sequence-specific oligonucleotide-PCR
      • 7.2.1.2.1 Growing applications of PCR in donor-recipient matching, cancer, rheumatoid, and arthritis to drive market
    • 7.2.1.3 Real-time PCR
      • 7.2.1.3.1 Increasing preference for genome-based molecular diagnostics to facilitate growth
    • 7.2.1.4 Other PCR-based molecular assays
  • 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
    • 7.2.2.1 Sanger sequencing
      • 7.2.2.1.1 Increasing use of sanger sequencing in clinical settings for organ and bone marrow transplantations to aid growth
    • 7.2.2.2 Next-generation sequencing
      • 7.2.2.2.1 Growing reliance on outsourcing to fuel market
    • 7.2.2.3 Other sequencing-based molecular assays
• 7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
  • 7.3.1 RISING IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO AUGMENT GROWTH

8 HLA TYPING MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC APPLICATIONS
  • 8.2.1 DONOR-RECIPIENT CROSS-MATCHING
    • 8.2.1.1 Increasing focus on successful organ transplants to foster growth
  • 8.2.2 INFECTIOUS DISEASE TESTING
    • 8.2.2.1 Rising prevalence of infectious diseases to accelerate growth
  • 8.2.3 CANCER DIAGNOSTIC & PREVENTION
    • 8.2.3.1 Increasing demand for accurate and early cancer diagnosis to bolster growth
  • 8.2.4 TRANSFUSION THERAPY
    • 8.2.4.1 Growing clinical evidence supporting hla typing to propel market
  • 8.2.5 OTHER DIAGNOSTIC APPLICATIONS
• 8.3 RESEARCH APPLICATIONS
  • 8.3.1 EXPANDING USE OF GENOMIC TECHNOLOGIES TO EXPEDITE GROWTH

9 HLA TYPING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 COMMERCIAL SERVICE PROVIDERS
  • 9.2.1 RISING DEMAND FOR OUTSOURCED SERVICES TO CONTRIBUTE TO GROWTH
• 9.3 HOSPITALS & TRANSPLANT CENTERS
  • 9.3.1 GROWING DEMAND FOR ORGAN TRANSPLANTS TO BOOST MARKET
• 9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
  • 9.4.1 INCREASING RESEARCH ACTIVITIES TO PROMOTE GROWTH

10 HLA TYPING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Expanding donor registries and precision medicine to propel market
  • 10.2.3 CANADA
    • 10.2.3.1 Evolving healthcare landscape to augment growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Growing investments in genomic research and digital healthcare to drive market
  • 10.3.3 UK
    • 10.3.3.1 Strong healthcare infrastructure and centrally coordinated transplant system to foster growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Growing adoption for donor-recipient compatibility testing to boost market
  • 10.3.5 SPAIN
    • 10.3.5.1 Increasing solid organ transplantation procedures to facilitate growth
  • 10.3.6 ITALY
    • 10.3.6.1 Supportive government policies and strong healthcare infrastructure to promote growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing utilization of hla typing for donor-recipient matching to propel market
  • 10.4.3 JAPAN
    • 10.4.3.1 Growing burden of chronic diseases to boost market
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing government efforts to offer free access to support growth
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Advanced healthcare to contribute to growth
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 Increasing integration of genomic tools in diagnostics to promote growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Growing adoption of next-generation sequencing to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Supportive business environment to bolster growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Improvements in healthcare infrastructure to spur growth
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HLA TYPING MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
• 11.6 PRODUCT/BRAND COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Product footprint
    • 11.7.5.4 Technology footprint
    • 11.7.5.5 Application footprint
    • 11.7.5.6 End-user footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2024
    • 11.8.5.1 Detailed list of key startup/sme players
    • 11.8.5.2 Competitive benchmarking of startups/smes
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 MAJOR PLAYER
  • 12.1.1 BD
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Mnm view
      • 12.1.1.3.1 Key Strengths
      • 12.1.1.3.2 Strategic choices
      • 12.1.1.3.3 Weaknesses and competitive threats
  • 12.1.2 THERMO FISHER SCIENTIFIC INC.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches and approvals
      • 12.1.2.3.2 Deals
      • 12.1.2.3.3 Expansions
    • 12.1.2.4 Mnm view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 ILLUMINA, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Expansions
    • 12.1.3.4 Mnm view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 QIAGEN
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches and approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 Mnm view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 BIO-RAD LABORATORIES, INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches and approvals
    • 12.1.5.4 Mnm view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 F. HOFFMANN-LA ROCHE LTD
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches and approvals
      • 12.1.6.3.2 Expansions
    • 12.1.6.4 Mnm view
      • 12.1.6.4.1 Key strengths
      • 12.1.6.4.2 Strategic choices
      • 12.1.6.4.3 Weaknesses and competitive threats
  • 12.1.7 CAREDX, INC.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches and approvals
      • 12.1.7.3.2 Deals
  • 12.1.8 WERFEN
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches and approvals
      • 12.1.8.3.2 Deals
  • 12.1.9 DIASORIN S.P.A.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches and approvals
  • 12.1.10 TBG BIOTECHNOLOGY CORPORATION
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches and approvals
      • 12.1.10.3.2 Deals
  • 12.1.11 FUJIREBIO
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Deals
  • 12.1.12 EUROBIO SCIENTIFIC
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches and approvals
      • 12.1.12.3.2 Deals
  • 12.1.13 PACBIO
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches and approvals
      • 12.1.13.3.2 Deals
  • 12.1.14 BAG DIAGNOSTICS GMBH
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 CREATIVE BIOLABS
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 HISTOGENETICS LLC
  • 12.2.2 SCISCO GENETICS, INC.
  • 12.2.3 INNO-TRAIN DIAGNOSTIK GMBH
  • 12.2.4 BIONOBIS
  • 12.2.5 TAKARA BIO INC.
  • 12.2.6 KRISHGEN BIOSYSTEMS
  • 12.2.7 SCIENCELL RESEARCH LABORATORIES, INC.
  • 12.2.8 PROIMMUNE LTD.
  • 12.2.9 BIOFORTUNA LIMITED
  • 12.2.10 ALPHA BIOTECH LIMITED

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS